Agenda

Programme

Friday: September 21, 2018

18.30 - 20.00

Welcome Reception

Saturday: September 22, 2018

07.30 - 08.00

Breakfast

08.00

Meeting Registration

08.30

Introduction & Meeting Objectives
John Gribben & Anas Younes

08.45 - 10.15

Session I: Pathobiology and Clinical Management of T-Cell Lymphoma

Chairs: Laurence de Leval & Francine Foss

  • Introduction/update on pathology and genetics; Laurence de Leval
  • TCR signaling and PD1 in T-cell lymphomagenesis and implications for therapies; Jurgen Ruland
  • Immunotherapy in the treatment of mature T and NK cell lymphomas; Francine Foss

Roundtable Discussion:
Laurence de Leval, Francine Foss & Session Speakers

10.15 - 10.45

Coffee Break

10.45 - 12.15

Session II: Novel Diagnostics & Biomarkers

Chairs: Owen O'Connor & Andreas Rosenwald

  • Actionable Genetic Signatures in DLBCL; Bjoern Chapuy
  • PTCL; how to optimize the best predictive biomarkers; Ryan Wilcox
  • Biomarkers for diagnosis and treatment of cutaneous T-cell lymphomas; Nicolas Ortonne
  • Predictive biomarkers that help stratify responders to immunotherapies; Scott Rodig

Roundtable Discussion:
Owen O'Connor, Andreas Rosenwald & Session Speakers

12.15 - 13.15

Lunch

13.15 - 14.45

Session III: Viral Driven Lymphoma

Chairs: Cath Bollard & Kieron Dunleavy

  • Risk factors for EBV-associated lymphomas; Ruth Jarrett
  • PTLD & LYG; Mark Roschewski
  • HIV associated lymphomas; Richard Little
  • Cell therapies for virally driven lymphomas (HIV, EBV); Cath Bollard

Roundtable Discussion:
Cath Bollard, Wyndham Wilson & Session Speakers

14.45 - 15.00

Coffee Break

15.00 - 17.00

Session IV: Immunotherapy of Lymphoma

Chairs: Steve Ansell & John Gribben

  • Beyond PD-1 blockade alone – combination approaches; Robert Chen
  • Targeting PD-1 in immune activated situations; John Gribben
  • New immune therapies for lymphoma (LAG-3/TIGIT/4-1BB/CD47/bi-specifics); Stephen Ansell

Roundtable Discussion:
Steve Ansell & Session Speakers

19.00

16th iwNHL Dinner

Sunday: September 23, 2018

08.00 - 08.30

Breakfast

08.30 - 10.30

Session V: Precision Medicine

Chairs: Anas Younes & Tom Witzig

  • Introduction to precision medicine trials in lymphoma; Anas Younes
  • Precision medicine in follicular lymphoma; Franck Morschhauser
  • Precision medicine across different histologic subtypes; Tom Witzig
  • ctDNA to guide therapy; Davide Rossi

Roundtable Discussion:
Anas Younes & Session Speakers

10.30 - 10.45

Coffee Break

10.45 - 13.00

Session VI: Novel Lymphoma Targets/Agents

Chairs: Franck Morschhauser & Laurie Sehn

  • Selinexor: best partners to combine with; John Kuruvilla
  • SYK-JAK inhibitors: Certulatinib versus other SYK inhibitors; Ryan Wilcox
  • BTK inhibitors beyond approved indications; Anas Younes
  • MCL-1 inhibitors; Francisco Hernandez Ilizaliturri
  • New indications for venetoclax: T-PLL, Other niche; Sven de Vos
  • Any future for demethylating agents in DLBCL (Azacytidine?); Andrew Davies
  • Polatuzumab-including combination regimen in R/R NHL; Laurie Sehn
  • Umbralisib combinations in NHL subtypes; George Deng
  • Optimal Therapy for MYC-positive, Double-Hit & Triple-Hit DLBCL; Kieron Dunleavy

Roundtable Discussion:
Frank Morschhauser, Laurie Sehn & Session Speakers

13.00 - 13.45

Lunch

13.45 - 16.00

Session VII: CAR-T in Lymphoma

Chair: Dave Maloney & Caron Jacobson

  • Off to the CAR-T Races; David Maloney
  • Current standards for treatment & prevention of toxicities related to CAR-T; Jim Kochenderfer
  • Neurotoxicity; Bianca Santomasso
  • Anti-CD19 CAR-T Cells in aggressive NHL; Steve Schuster
  • CAR-T cells- moving to commercialization; William Go (VP, Clinical Development,Kite Pharma)

Roundtable Discussion:
Dave Maloney, Caron Jacobson & Session Speakers

16.00 - 16.15

Final Meeting Summary & Conclusions
iwNHL Committee

16th International Workshop on Non-Hodgkin Lymphoma

Nice, France

Sep

21–23

2018 Meeting

Location

Hotel Le Meridien
1 Prom. des Anglais, 06046 Nice, France

© 2014 - 2019 World Health Communications Ltd